Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled,
parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine
during acute and long-term treatment in approximately 5,500 patients with non-ST elevation
acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint
in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of
cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST
elevation ACS receiving standard therapy. The study also evaluates the safety of long-term
treatment with ranolazine compared to placebo.